Interpace Biosciences, Inc. (OTCPK: IDXG)
Health Care · Health Care Providers & Services · US
$1.52
-8.27% today · +79.2% 1Y
Interpace Biosciences, Inc. (OTCPK: IDXG) operates in the Health Care Providers & Services industry within the Health Care sector. The company is valued at $42.18M and employs 102 people.
Over the last twelve months the share price has gained 79.2%, trading between 0.77 and 2.40.
Tweenvest scores Interpace Biosciences, Inc. across four factors: quality 77/100, value 40/100, growth 50/100. Its strongest factor is quality.
IDXG price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $42.18M
- Revenue (TTM)
- $36.14M
- P/E
- 1.68
- EPS
- 0.89
- Dividend yield
- —
- Beta (5Y)
- 0.61
- 52-week high
- $2.40
- 52-week low
- $0.77
- Avg volume (3M)
- —
- Shares outstanding
- 27.70M
- Employees
- 102
- Next earnings
- —
About Interpace Biosciences, Inc.
Interpace Biosciences, Inc. is a U.S.-based company specializing in advanced molecular diagnostic tests, bioinformatics, and pathology services, primarily focused on assessing cancer risk. Among its key offerings is PancraGEN, a comprehensive genomic test for pancreatic cysts and solid lesions within the pancreaticobiliary system. This test, powered by the proprietary PathFinderTG platform, assists medical professionals in more accurately determining the risk of pancreaticobiliary cancers. It also offers PanDNA, a molecular-only variant of PancraGEN, which delivers insights into a select number of diagnostic markers. For thyroid health, the company provides ThyGeNEXT, an oncogenic mutation panel designed to identify malignant thyroid nodules. Additionally, ThyraMIR evaluates thyroid nodules for malignancy risk through the application of its proprietary microRNA gene-expression assay. Furthermore, RespriDx is a genomic diagnostic tool that aids clinicians in distinguishing between metastatic and recurrent lung cancer. Interpace Biosciences further supports the pharmaceutical and biotechnology sectors with services including pharmacogenomics testing, genotyping, biorepository solutions, and various custom scientific offerings. Its clientele primarily consists of physicians, hospitals, and clinics. Previously operating as Interpace Diagnostics Group, Inc., the company adopted its current name, Interpace Biosciences, Inc., in November 2019. Founded in 1986, its corporate headquarters are located in Parsippany, New Jersey.
- ISIN
- US46062X3035
- Founded
- 1986
- Listed since
- May 20, 1998
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Health Care Providers & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| UnitedHealth Group IncorporatedNYSE: UNH | $350.16B | $391.52 | +0.36% |
| CVS Health CorporationNYSE: CVS | $118.97B | $93.11 | +0.10% |
| McKesson CorporationNYSE: MCK | $100.14B | $861.48 | +0.30% |
| HCA Healthcare, Inc.NYSE: HCA | $92.92B | $429.19 | +5.64% |
| Elevance Health, Inc.NYSE: ELV | $86.86B | $400.54 | +1.07% |
| The Cigna GroupNYSE: CI | $73.33B | $277.51 | +1.13% |
| Cencora, Inc.NYSE: COR | $60.69B | $320.72 | +0.84% |
| Cardinal Health, Inc.NYSE: CAH | $53.38B | $229.51 | +0.46% |
Figures last refreshed Aug 18, 2026.